<p>WCDD301 is an oral drug that agonizes EphA4 receptors in &alpha;-cells to suppress glucagon hypersecretion and normalize hyperglycemia in type 1 diabetes.</p>. This evidence concerns the gene GCG and type 1 diabetes mellitus.